Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Novartis
Eli Lilly and Company
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Montefiore Medical Center
Tango Therapeutics, Inc.
Hoosier Cancer Research Network
Actuate Therapeutics Inc.
NRG Oncology
NRG Oncology
NRG Oncology
Mayo Clinic
Institut Cancerologie de l'Ouest
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
Avera McKennan Hospital & University Health Center